智通财经APP获悉，复锐医疗科技(01696)涨超5%，截至发稿，涨5.64%，报3.37港元，成交额225.61万港元。
消息面上，复锐医疗科技公布，由上海复星医药产业发展再授权产品注射用A型肉毒毒素，(中国境内商标达希斐®)用于暂时性改善成人因皱眉肌或降眉间肌活动引起的中度至重度眉间纹的药品注册申请于近日收到国家药品监督管理局的批准。
复锐医疗科技表示，此次该产品的注册批准将成为公司推向中国内地的首款注射填充产品。作为注射填充产品矩阵中的核心产品，达希斐®在业务发展过程中将持续发挥其基石作用，并不断加强公司在中国内地的产品组合和差异化竞争优势，持续贡献新的收入来源。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.